Original Article

MiR-205 Regulates LRRK2 Expression in Dopamine Neurons in Parkinson's Disease through Methylation Modification

Abstract

Background: We explored the methylation modification in miR-205 promoter during the pathological changes of Parkinson's disease (PD) and its regulation on Leucine-Rich Repeat Kinase 2 (LRRK2), clarified the important role of methylation in miR-205 promoter region in PD, explained the role of miR-205 methylation in the pathological changes of PD, and looked for new targets for PD.

Methods: Methylation of miR-205 promoter regions was determined by cell genomic DNA, with model bisulfite treatment, and the transcription of miR-205 and LRRK2 in PD model cells was determined by qPCR, and LRRK2 expression was determined by Western blot. The binding sites of miRNAs in the non-coding region of LRRK2 were analyzed by the targetscan database, and miR-205 expression in 293T cells was controlled. The correlation between miR-205 expression and LRRK2 was determined to clarify the regulation mode of miR-205 on LRRK2.

Results: The level of miR-205 were reduced in the SH-SY5Y Parkinson model cells, and its promoter region was highly methylated, while LRRK2 expression decreased in the model cells after 5-Azacytidine inhibition of methylation in miR-205 promoter region. According to the target scan database analysis, LRRK2 non-coding region is a miR-205-specific binding site. After further miR-205 overexpression in 293T cells, the transcription and translation of LRRK2 decreased in cells, which increased after the treatment of miR-205 inhibitor on LRRK2.

Conclusion: The methylation modification of miR-205 promoter region could regulate the transcription and translation of LRRK2 in dopaminergic neurons, so miR-205 methylation regulation can serve as a new potential target for the treatment of PD.

1. Lee A, Gilbert RM (2016). Epidemiology of Parkinson Disease. Neurol Clin, 34: 955-965.
2. Belvisi D, Pellicciari R, Fabbrini A, et al (2020). Risk factors of Parkinson disease: Simultaneous assessment, interactions, and etiologic subtypes. Neurology, 95: e2500-e2508.
3. Tsika E, Nguyen AP, Dusonchet J, Colin P, Schneider BL, Moore DJ (2015). Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis, 77: 49-61.
4. Antonini A, Albin RL (2013). Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology, 80: 784-785.
5. Schapira AH, Gegg ME (2013). Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Mov Disord, 110: 3214-3215.
6. Titova N, Qamar MA, Chaudhuri KR (2017). The Nonmotor Features of Parkinson's Disease. Int Rev Neurobiol, 132: 33-54.
7. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R (2008). LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol, 34: 272-283.
8. Wu X, Tang KF, Li Y, et al (2012). Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord, 18: 722-730.
9. Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG (2011). Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci, 7: 753-761.
10. Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y (2013). Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation. Gastroenterol Res Pract, 2013: 719202.
11. Moghadasi M, Alivand M, Fardi M, Moghadam KS, Solali S (2020). Emerging molecular functions of microRNA-124: Cancer pathology and therapeutic implications. Pathol Res Pract, 216: 152827.
12. Patil KS, Basak I, Pal R, Ho HP, Alves G, Chang EJ, Larsen JP, Moller SG (2015). A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. PloS One, 10: e0143969.
13. Song H, Bu G (2009). MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. Biochem Biophys Res Commun, 388: 400-405.
14. Cho HJ, Liu G, Jin SM, et al (2013). MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet, 22: 608-620.
15. Ross RA, Spengler BA, Biedler JL (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst, 71: 741-747.
16. Kovalevich J, Langford D (2013). Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol, 1078: 9-21.
17. Xie H, Hu H, Chang M, Huang D, Gu X, Xiong X, Xiong R, Hu L, Li G (2016). Identification of chaperones in a MPP(+)-induced and ATRA/TPA-differentiated SH-SY5Y cell PD model. Am J Transl Res, 8: 5659-5671.
18. Pieper HC, Evert BO, Kaut O, Riederer PF, Waha A, Wullner U (2008). Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiol Dis, 32: 521-527.
19. Yuan J, Kang J, Yang M (2020). Long non-coding RNA ELF3-antisense RNA 1 promotes osteosarcoma cell proliferation by upregulating Kruppel-like factor 12 potentially via methylation of the microRNA-205 gene. Oncol Lett, 19: 2475-2480.
20. Kraus TFJ, Haider M, Spanner J, Steinmaurer M, Dietinger V, Kretzschmar HA (2017). Altered Long Noncoding RNA Expression Precedes the Course of Parkinson's Disease-a Preliminary Report. Mol Neurobiol, 54: 2869-2877.
21. Lovkvist C, Dodd IB, Sneppen K, Haerter JO (2016). DNA methylation in human epigenomes depends on local topology of CpG sites. Nucleic Acids Res, 44: 5123-5132.
22. Dubouzet JG, Morishige T, Fujii N, An CI, Fukusaki E, Ifuku K, Sato F (2005). Transient RNA silencing of scoulerine 9-O-methyltransferase expression by double stranded RNA in Coptis japonica protoplasts. Biosci Biotechnol Biochem, 69: 63-70.
23. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA (2006). Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9: 435-443.
24. Liu G, Cao P, Chen H, Yuan W, Wang J, Tang X (2013). MiR-27a regulates apoptosis in nucleus pulposus cells by targeting PI3K. PloS One, 8: e75251.
25. Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120: 15-20.
26. Breit S, Wachter T, Schmid-Bielenberg D, et al (2010). Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease. J Neurol, 257: 1205-1207.
27. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391: 806-811.
28. Mochizuki H (2009). Parkin gene therapy. Parkinsonism Relat Disord, 15 Suppl 1: S43-5.
29. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411: 494-498.
30. Kim MH, Yuan X, Okumura S, Ishikawa F (2002). Successful inactivation of endogenous Oct-3/4 and c-mos genes in mouse preimplantation embryos and oocytes using short interfering RNAs. Biochem Biophys Res Commun, 296: 1372-1377.
31. Gehrke S, Imai Y, Sokol N, Lu B (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466: 637-641.
Files
IssueVol 51 No 7 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v51i7.10098
Keywords
Parkinson's disease miR-205 RNA interference
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Wang H, Li J, Tao L, Lv L, Sun J, Zhang T, Wang H, Wang J. MiR-205 Regulates LRRK2 Expression in Dopamine Neurons in Parkinson’s Disease through Methylation Modification. Iran J Public Health. 2022;51(7):1637-1647.